Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
66 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
CONVERT PHARMACEUTICALS from Liège, company number BE0671828631, closed financial year 2025 with a result of € -629,343 after tax. For that financial year CONVERT PHARMACEUTICALS recorded a gross margin of € -247,884 and equity of € -841,823. Compared with financial year 2024, the result moved from € -645,819 to € -629,343. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ -841,823
▲ € 323,154 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -629,343
▲ 3 % less loss than in 2024
Profit after tax over the fiscal year.
€ 158,318
▼ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4.2 million.
Debts at end 2025
€ 1.5 million
▼ 27% vs 2024
Loans from banks and other lenders, long and short.
€ 277,698
▲ € 223,488 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 78,406 | € -80,305 | € -513,906 | € -247,884 | ▲ € 266,022 |
| Profit after taxes | € -501,407 | € -616,326 | € -645,819 | € -629,343 | ▲ € 16,476 |
| Equity | € -798,184 | € -1,414,510 | € -1,164,977 | € -841,823 | ▲ € 323,154 |
| Total debts | € 1,837,409 | € 1,771,664 | € 2,381,431 | € 1,783,027 | ▼ 25% |
| Cash | € 527,657 | € 75,127 | € 551,649 | € 158,318 | ▼ 71% |
| Retained profit | € -2,318,370 | € -2,934,696 | € -3,580,515 | € -4,209,858 | ▼ € 629,343 |
| Bank debt | € 1,725,095 | € 1,750,467 | € 2,068,221 | € 1,505,330 | ▼ 27% |
| Balance sheet total | € 1,039,225 | € 357,154 | € 1,216,454 | € 941,204 | ▼ 23% |
| Employees (FTE) | 0.3 | 66,197.7 | - | - |
Key figures of CONVERT PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CONVERT PHARMACEUTICALS?
What happened at CONVERT PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 629,343. Source: NBB ↗
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 501,407 loss in 2022 to € 629,343 loss in 2025.
Paid € 273,989 in corporate taxes since 2022.
A new publication or filing at CONVERT PHARMACEUTICALS? We notify you, reason included.
Follow CONVERT PHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Esplanade Simone VEIL 1
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 66 companies are registered at this address.
All companies at this address →Liège Real Estate srl
€ 119,509 gross margin · 2025
WAN VOYAGE - ARTS ET CULTURES EN VOYAGE
€ 233,124 gross margin · 2025
KOMPAN COMMERCIAL SYSTEMS
€ 16.2 million revenue · 2025
Three-E
€ 61,402 gross margin · 2025
GROUPASOL
€ 401,444 gross margin · 2024
+61 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
EQUINIX-NL-ASN, NL
Domain
Domain
convertpharma.com
Registered
2017-01-09
Registrar
Key-Systems GmbH
Expires
2027-01-09
Website info
Features
Security
Details
- Company number
- 0671.828.631
- VAT number
- BE 0671.828.631
- Registered office
- Esplanade Simone VEIL 1, 4000 Liège
- Names & denominations
- CONVERT PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 February 2017
- Peppol
- Active · Active since 5 Dec 2025
- Contact
- convertpharma.com
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied